Deferiprone modulates osteoclast‐mediated bone resorption while preserving axial bone microstructure in β‐thalassemic mice with iron overload

Deferiprone (DFP), an iron chelator, is widely used to alleviate iron overload. However, its effects on bone metabolism remain incompletely understood. Herein, we demonstrated that DFP reduced osteoblast viability and in vitro mineralization. Interestingly, DFP delayed osteoclastogenesis, suppressed osteoclast marker expression, and appeared to influence iron efflux by upregulating Nrf2 and ferroportin-1. Although DFP effectively reduced iron accumulation in bone, it did not reverse persistent microstructural defects in the axial skeleton of β-thalassemic mice. Under high-iron conditions, DFP appeared to increase osteoclast turnover, leading to a transient accumulation of multinucleated osteoclasts followed by enhanced apoptosis. Collectively, our findings suggest a trade-off whereby reduced iron toxicity is accompanied by attenuated bone formation and resorption in β-thalassemic mice.

Authors

Institutions

Publication Details

Journal
FEBS Letters
Published
2026-11-18
DOI
https://doi.org/10.1002/1873-3468.70504
Primary Topic
Bone Metabolism and Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Deferiprone modulates osteoclast‐mediated bone resorption while preserving axial bone microstructure in β‐thalassemic mice with iron overload

Jirawan Thongbunchoo, Jarinthorn Teerapornpuntakit, Jiraporn Panmanee, Parinda Jamrus et al.
2 links
FEBS Letters
Bone Metabolism and Diseases
article

Deferiprone modulates osteoclast‐mediated bone resorption while preserving axial bone microstructure in β‐thalassemic mice with iron overload

Jirawan Thongbunchoo, Jarinthorn Teerapornpuntakit, Jiraporn Panmanee, Parinda Jamrus, Ratchaneevan Aeimlapa, Nuttanan Pholngam, Narattaphol Charoenphandhu, Saovaros Svasti, Pathnaree Wattano, Benjaporn Kiatpakdee
article en

Abstract

Deferiprone (DFP), an iron chelator, is widely used to alleviate iron overload. However, its effects on bone metabolism remain incompletely understood. Herein, we demonstrated that DFP reduced osteoblast viability and in vitro mineralization. Interestingly, DFP delayed osteoclastogenesis, suppressed osteoclast marker expression, and appeared to influence iron efflux by upregulating Nrf2 and ferroportin-1. Although DFP effectively reduced iron accumulation in bone, it did not reverse persistent microstructural defects in the axial skeleton of β-thalassemic mice. Under high-iron conditions, DFP appeared to increase osteoclast turnover, leading to a transient accumulation of multinucleated osteoclasts followed by enhanced apoptosis. Collectively, our findings suggest a trade-off whereby reduced iron toxicity is accompanied by attenuated bone formation and resorption in β-thalassemic mice.

FEBS Letters
Thammasat University (TH), Mahidol University (TH), Office of the Royal Society (TH)
Good health and well-being
Bone Metabolism and Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon